Quick Answer
Oncology Institute, Inc. reported Total Revenue of $502.73 million for the year ending 2025.
- Oncology Institute, Inc. showed an increase of +27.8% in Total Revenue from 2024 to 2025.
- This data is from Oncology Institute, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $48.58 million | Q2 2021: $49.84 million | Q3 2021: $52.28 million | Q1 2022: $55.16 million | Q2 2022: $60.92 million | Q3 2022: $64.98 million | Q1 2023: $76.19 million | Q2 2023: $80.22 million | Q3 2023: $82.04 million | Q1 2024: $94.67 million | Q2 2024: $98.58 million | Q3 2024: $99.90 million | Q1 2025: $104.41 million | Q2 2025: $119.80 million | Q3 2025: $136.56 million.
- Over the full 6 years of available data (2020 to 2025), Oncology Institute, Inc.'s Total Revenue has grown by 168.1%.
- Historical annual values: Fiscal year 2025: $502.73 million | Fiscal year 2024: $393.41 million | Fiscal year 2023: $324.24 million | Fiscal year 2022: $252.48 million | Fiscal year 2021: $203.00 million | Fiscal year 2020: $187.52 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: